87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7

Semaglutide and dulaglutide are glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes (T2D). In SUSTAIN 7, an international, open-label, parallel group trial, adults with inadequately controlled T2D were randomized (1:1:1:1) to once-weekly subcutaneous semaglutide or dulaglutide at low (0.5 vs 0.75 mg) or high (1.0 vs 1.5 mg) doses. Semaglutide provided superior glycemic control and reductions in body weight at both low...